Fetal therapy: intrauterine transfusion, fetal medicines and surgery
- Topic
Some problems can be treated before birth: blood transfusions to an anemic fetus, medicines given through the mother, and operations on the fetus or placenta.
What it is
Fetal therapy treats the fetus while it is still in the uterus, when waiting until birth would cause death or permanent damage. Approaches range from medicines given to the mother that cross the placenta, to ultrasound-guided needle procedures such as intrauterine transfusion and shunts, to fetoscopic and open surgery. Every intervention also exposes the mother, so it is offered only for well-defined conditions in specialized centers. Weeks on this page are gestational weeks (from the last menstrual period).
Key facts
- Fetal therapy began in the 1960s with intrauterine transfusion for Rh disease.
- The fetus is a patient, but every procedure is done through the mother, who bears its risks without direct benefit.
- Prevention with anti-D immunoglobulin in Rh-negative mothers has made severe Rh disease rare where it is used.
- Prenatal dexamethasone to reduce virilization of female fetuses with congenital adrenal hyperplasia remains controversial and is considered experimental in many guidelines.
- In utero stem cell transplantation, enzyme replacement and gene therapy are under research and are not standard care.
- Radiofrequency ablation or cord occlusion stops flow to an acardiac twin (TRAP sequence) and is used in selected complicated twin pregnancies.
- Fetal anaemia is detected without needles: a raised peak systolic velocity in the middle cerebral artery on Doppler (thinner, faster-flowing blood) selects the fetuses who need cordocentesis and transfusion.
- Twin–twin transfusion syndrome is staged by ultrasound (Quintero stages, from fluid imbalance alone up to hydrops or death of a twin); fetoscopic laser is offered for the more advanced stages within a mid-pregnancy window, roughly 16 to 26 weeks.
- Shunts help only when the organ is still worth saving: for lower urinary tract obstruction, a normal amount of amniotic fluid before the block, a normal karyotype and fetal urine that still looks like functioning kidneys select the candidates.
Which fetal problem, which therapy, and why it works
| Condition | What harms the fetus before birth | Therapy | Why it works |
|---|---|---|---|
| Red cell alloimmunization (anti-D) | Maternal antibodies destroy fetal red cells: anemia, heart failure, hydrops | Intrauterine transfusion into the umbilical vein | Replaces the destroyed red cells |
| Parvovirus B19 infection | The virus halts red cell production: anemia, hydrops | Intrauterine transfusion | Bridges the gap until the marrow recovers |
| Twin–twin transfusion syndrome | Shared placental vessels shunt blood: one twin overloaded, the other depleted | Fetoscopic laser coagulation | Seals the connecting vessels |
| Severe congenital diaphragmatic hernia | Abdominal organs in the chest stop the lungs growing | Fetoscopic tracheal occlusion (FETO) | Retained lung fluid stretches and grows the lungs |
| Myelomeningocele | The exposed cord is damaged in utero; hindbrain herniates | Prenatal repair before about 26 weeks | Covers the cord; less shunt-dependent hydrocephalus |
| Supraventricular tachycardia | A fast rate leads to heart failure and hydrops | Antiarrhythmic given to the mother | The drug crosses the placenta |
| Large pleural effusion or lower urinary tract obstruction | Fluid compresses the lungs or backs up into the kidneys | Shunt into the amniotic cavity | Drains the fluid |
| Neck mass blocking the airway | No airway at the moment of birth | EXIT procedure | Airway secured while the placenta still oxygenates |
Clinical notes
- Untreated severe fetal anemia leads to high-output heart failure and hydrops (fluid in skin, pleura, pericardium and abdomen).
- Twin–twin transfusion: one twin becomes overloaded with polyhydramnios and the other depleted with oligohydramnios through shared placental vessels.
- In diaphragmatic hernia, survival depends mainly on lung growth, which is why tracheal occlusion is tried in severe cases.
- Children after fetal therapy are followed for neurodevelopment, because prematurity and the underlying disease both carry risk.
Common traps
- Fetal therapy only involves the fetus: every procedure goes through the mother, who bears its risks without direct benefit
- Prenatal myelomeningocele repair cures the defect: it reduces shunt need and improves motor outcome, but deficits remain and preterm birth is more likely
- Detecting fetal anemia needs a fetal blood sample: middle cerebral artery Doppler detects it without a needle; blood is sampled during the transfusion itself
- Twin–twin transfusion can occur in any twin pregnancy: it needs a shared (monochorionic) placenta with vessel connections
Test yourself
Think of the answer, then tap the question to see it.
A fetus at 26 weeks of gestation, whose mother has anti-D antibodies, has a high middle cerebral artery peak velocity. What does this mean, and what follows?
Fetal anemia: thinner blood flows faster. An ultrasound-guided intrauterine transfusion of red cells into the umbilical vein follows.
Monochorionic twins at 20 weeks of gestation: one has polyhydramnios and a large bladder, the other no visible bladder. What is it, and what is the treatment?
Twin–twin transfusion syndrome through shared placental vessels. Fetoscopic laser coagulation of the connecting vessels is the standard treatment.
Why does tracheal occlusion help lungs grow in diaphragmatic hernia?
Fetal lungs secrete fluid; blocking the trachea keeps it inside, and the stretch stimulates lung growth.
Which maternal risks limit open fetal surgery?
Preterm rupture of membranes and preterm labor, bleeding and infection, and a uterine scar that affects later pregnancies.
Connections
Educational content on embryonic development; not a guide to prenatal diagnosis or to medicines in pregnancy and no substitute for a health professional's advice. No doses are given.
Sources: Fetal therapies as standard prenatal care in Japan (Obstetrics & Gynecology Science (PMC), 2020); Hemolytic Disease of the Fetus and Neonate (MSD Manual Professional Edition, 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
